STOCK TITAN

Broadwood boosts Insight Molecular (IMDX) stake with 182,861-share buy

Filing Impact
(Very High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Insight Molecular Diagnostics Inc. shareholder entities associated with Broadwood Partners, L.P. and Neal C. Bradsher reported open-market purchases of 182,861 shares of common stock. The shares were bought between April 16 and April 20 at weighted average prices of $3.4457, $3.5711, and $3.8822 per share, across specified price ranges disclosed in the footnotes.

Following these transactions, Broadwood Partners is shown with 12,114,700 indirectly owned Insight Molecular common shares, while Neal C. Bradsher directly owns a small additional common stock position. The filing also lists currently exercisable warrants, held both directly and indirectly, each for 150,093 underlying shares at an exercise price of $30.60 per share expiring on April 19, 2027.

Positive

  • None.

Negative

  • None.
Insider BROADWOOD PARTNERS, L.P., BROADWOOD CAPITAL INC, Bradsher Neal C
Role null | null | null
Bought 182,861 shs ($653K)
Type Security Shares Price Value
Purchase Common Stock, no par value 40,690 $3.8822 $158K
Purchase Common Stock, no par value 0 $0.00 --
Purchase Common Stock, no par value 40,114 $3.5711 $143K
Purchase Common Stock, no par value 0 $0.00 --
Purchase Common Stock, no par value 102,057 $3.4457 $352K
Purchase Common Stock, no par value 0 $0.00 --
holding Warrant to Purchase Common Stock -- -- --
holding Warrant to Purchase Common Stock -- -- --
holding Common Stock, no par value -- -- --
Holdings After Transaction: Common Stock, no par value — 12,114,700 shares (Direct, null); Common Stock, no par value — 12,114,700 shares (Indirect, Footnote); Warrant to Purchase Common Stock — 150,093 shares (Direct, null); Warrant to Purchase Common Stock — 150,093 shares (Indirect, Footnote)
Footnotes (1)
  1. The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. These securities are directly owned by Neal C. Bradsher. This constitutes the weighted average purchase price. The prices range from $3.20 to $3.59. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. This constitutes the weighted average purchase price. The prices range from $3.45 to $3.84. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. This constitutes the weighted average purchase price. The prices range from $3.75 to $3.99. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. These warrants are currently exercisable.
Net shares purchased 182,861 shares Open-market common stock buys between April 16–20, 2026
Weighted average price 16 Apr 2026 $3.4457/share Purchase of 102,057 common shares
Weighted average price 17 Apr 2026 $3.5711/share Purchase of 40,114 common shares
Weighted average price 20 Apr 2026 $3.8822/share Purchase of 40,690 common shares
Indirect common shares after trades 12,114,700 shares Common stock indirectly owned by Broadwood Partners after purchases
Direct common shares holding entry 157 shares Direct common stock position shown as of April 16, 2026
Warrant exercise price $30.60/share Warrants on 150,093 underlying shares held directly and 150,093 indirectly
Warrant expiration April 19, 2027 Expiration date for listed Insight Molecular warrants
open-market purchase financial
"transaction_action: "open-market purchase" for common stock buys"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average purchase price financial
"Footnotes F3, F4, and F5 describe the prices as "weighted average purchase price""
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
pecuniary interest financial
"Footnote F1 states each Reporting Person disclaims beneficial ownership except to the extent of its or his pecuniary interest"
warrants financial
"Security titled "Warrant to Purchase Common Stock" with currently exercisable status"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
beneficial ownership financial
"Footnote F1 notes securities may be deemed to be beneficially owned by Broadwood Capital and Neal C. Bradsher"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BROADWOOD PARTNERS, L.P.

(Last)(First)(Middle)
C/O BROADWOOD CAPITAL INC.
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Insight Molecular Diagnostics Inc. [ IMDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, no par value04/16/2026P102,057A$3.4457(3)12,033,896D(1)
Common Stock, no par value04/16/2026P0A$012,033,896IFootnote(1)
Common Stock, no par value04/17/2026P40,114A$3.5711(4)12,074,010D(1)
Common Stock, no par value04/17/2026P0A$012,074,010IFootnote(1)
Common Stock, no par value04/20/2026P40,690A$3.8822(5)12,114,700D(1)
Common Stock, no par value04/20/2026P0A$012,114,700IFootnote(1)
Common Stock, no par value157D(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrant to Purchase Common Stock$30.6 (6)04/19/2027Common Stock150,093150,093D(1)
Warrant to Purchase Common Stock$30.6 (6)04/19/2027Common Stock150,093150,093IFootnote(1)
1. Name and Address of Reporting Person*
BROADWOOD PARTNERS, L.P.

(Last)(First)(Middle)
C/O BROADWOOD CAPITAL INC.
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
BROADWOOD CAPITAL INC

(Last)(First)(Middle)
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Bradsher Neal C

(Last)(First)(Middle)
C/O BROADWOOD CAPITAL, INC.
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
2. These securities are directly owned by Neal C. Bradsher.
3. This constitutes the weighted average purchase price. The prices range from $3.20 to $3.59. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
4. This constitutes the weighted average purchase price. The prices range from $3.45 to $3.84. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
5. This constitutes the weighted average purchase price. The prices range from $3.75 to $3.99. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
6. These warrants are currently exercisable.
Broadwood Partners, L.P., By: Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President04/20/2026
Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President04/20/2026
/s/ Neal C. Bradsher04/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What prices were paid for the new IMDX share purchases?

The reported weighted average prices were $3.4457, $3.5711, and $3.8822 per share. Footnotes explain these averages reflect trades within price ranges from $3.20–$3.99, and detailed trade-by-trade pricing is available on request to the issuer or regulators.

How many Insight Molecular shares does Broadwood Partners now hold indirectly?

Broadwood Partners is shown holding 12,114,700 Insight Molecular common shares indirectly. This indirect position is attributed to Broadwood Partners, L.P., with Broadwood Capital, Inc. and Neal C. Bradsher potentially deemed beneficial owners to the extent of their pecuniary interest.

Who is attributed ownership of the reported IMDX securities in this Form 4?

The common shares are directly owned by Broadwood Partners, L.P., and some are directly owned by Neal C. Bradsher. Footnotes state other reporting persons may be deemed beneficial owners but disclaim ownership except to the extent of their pecuniary interest.